BALTIMORE, MD, March 4, 2025 – A groundbreaking study has uncovered a startling reality: generative AI tools like ChatGPT are already reshaping the freelance job market, slashing employment opportunities and pay for workers across all skill levels. Even top freelancers – those with the strongest track records – are suffering the greatest setbacks.
Contentious minerals deal has sparked a war of words between Trump and Zelensky, and could be announced later this week
Americans have probably heard the word “tariffs” more in the past month than in the past four years — and for good reason. Tariffs are central to President Donald Trump’s economic playbook, despite opposition from mainstream economists and trade experts.
An audio journey of how data and analytics save lives, save money and solve problems.
Ashley Smith
Public Affairs Coordinator
INFORMS
Catonsville, MD
[email protected]
443-757-3578
Explore our resources for multiple topics including:
Joe Biden will be the 46th president and that the Democrats have held onto the House. With the Election Day dust now settled, let’s take a look at the winners and losers, courtesy of the data.
The airline industry has been a major beneficiary of the vaccine euphoria. First Pfizer, then Moderna announced vaccine candidates with a promised effectiveness of 90% or more. This excited investors and airline executives alike, with visions of pent-up demand creating packed planes with filled middle seats.
Another wave of COVID-19 cases is now triggering another wave of panic buying across the country. But the Maryland Department of Commerce says it has no regulatory oversight on grocers in the state. At this point, it's up to each individual company to set purchasing limits on high-demand items. In some instances, stores are starting to see empty shelves again.
Scientists work at the mAbxience biosimilar monoclonal antibody laboratory plant in Garin, Buenos Aires province, on August 14, 2020, where an experimental coronavirus vaccine will be produced for Latin America. - Argentina will manufacture while Mexico will pack and distribute in Latin America, except of Brazil, the vaccine against COVID-19 developed by the University of Oxford and the AstraZeneca laboratory.
Two drug companies have now reported highly successful results from phase III trials of COVID-19 vaccines. On November 18 Pfizer and partner BioNTech said their vaccine was 95 percent effective at preventing the disease, based on full trial results. Two days earlier Moderna reported its vaccine was 94.5 percent effective, based on interim data.
OR/MS Today is the INFORMS member magazine that shares the latest research and best practices in operations research, analytics and the management sciences.
Access OR/MS Today Magazine
Analytics magazine showcases articles and research reports based on big data, AI, machine learning, data analytics and other new-age technologies.
Access Analytics Magazine